Inclusion Criteria:

          -  Had measurable disease according to Standard Diagnostic Criteria at the time of
             initial Multiple Myeloma diagnosis

          -  Meets criteria for symptomatic multiple myeloma at the time of induction chemotherapy

          -  Is transplant eligible based on clinician judgement

          -  Willing to undergo ASCT in first remission

          -  Achieve partial response or better with induction chemotherapy prior to ASCT according
             to the International Myeloma Working Group (IMWG) Uniform Response Criteria for
             Multiple Myeloma

          -  Be MRD+ disease upon restaging prior to stem cell collection and ASCT

          -  Eastern Cooperative Oncology Group (EGOG) performance status score of less than 2

          -  Life expectancy greater than six months

          -  Have no evidence of active or decompensated heart failure, no recent history (past 6
             months) acute myocardial infarction, no evidence of severe valvular disease and must
             have a LVEF over 50% at the time of transplant evaluation

          -  Adequate kidney function

          -  No evidence of moderate/severe restrictive or obstructive lung disease at the time of
             transplant evaluation

          -  Adequate bone marrow function

          -  Be willing to undergo CD34+ cell collection for stem cell transplant

          -  Be willing to undergo leukapherisis

          -  Adequate hepatic function

          -  If of child-bearing potential, be willing to follow birth control and pregnancy
             testing practice as recommended

          -  Be willing to undergo bone marrow aspirate and biopsy as per treatment plan

        Exclusion Criteria:

          -  Prior autologous or allogeneic hematopoietic stem cell transplant

          -  Prior cellular therapies, including NK cell therapy

          -  Prior treatment with monoclonal antibodies

          -  Prior treatment with melphalan

          -  Prior treatment with immunosuppressive or immunomodulatory agents within 30 days of
             enrollment

          -  Disease progression at the time of enrollment

          -  Non secretory multiple myeloma (defined as normal serum and urine immunofixation and
             normal serum free light chain assay)

          -  History of plasma cell leukemia at any time prior to enrollment

          -  Patients seropositive for the human immunodeficiency virus (HIV)

          -  Uncontrolled, Hepatitis C Virus or Hepatitis B Virus infection

          -  Patient receiving other investigational or anti-myeloma drugs within 30 days of
             enrollment

          -  Patients with active clinically significant autoimmune diseases

          -  Patients with active, clinically significant cancer other than multiple myeloma

          -  Patients with neurological conditions that make difficult the assessment of neurologic
             toxicity of the Combination Product